BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...NASDAQ:ALLO) and Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS). A fourth, Celyad S.A....
...those same two genes using TALEN-mediated editing. Celyad’s...
...Inc. Allogene Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. bluebird...
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

...NASDAQ:ALLO) and Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS). A fourth, Celyad S.A....
...those same two genes using TALEN-mediated editing. Celyad’s...
...Tuzman Allogene Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. CD19 CD22...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...in 1997-2018, most recently serving as a senior medical director. CAR T cell therapy company Celyad S.A....
...CRAC - Calcium release-activated calcium channel Robin Sawka, BioCentury Staff Quell Therapeutics Ltd. American Association for Cancer Research CalciMedica Inc. Celyad S.A. Confo...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...in clinical development and medical affairs at Boehringer Ingelheim GmbH. CAR T cell therapy company Celyad S.A....
...Inc. (NYSE:MRK) from March 2007 to December 2018. BioCentury Staff Applied Therapeutics Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...requiring modification of a patient’s own cells. However, there are nine allogeneic products in development. Celyad S.A....
...ligand 1 TSHR - Thyroid stimulating hormone receptor Winnie Pong, Associate Editor, Data & Analytics Bellicum Pharmaceuticals Inc. Celyad S.A. Programmed...
BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...trial Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A....
...GvHD) among the 12 evaluable patients; one patient experienced grade 1 cytokine release syndrome (CRS). Celyad...
...Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad S.A. Interleukin-2...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad...
...that allows you to do many of those steps in one single transduction.” Christian Homsy, Celyad...
...have made it more feasible to take advantage of its straightforward manufacturing and regulatory path. Celyad S.A....
BioCentury | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

...was acquired by Sanofi (Euronext:SAN; NASDAQ:SNY) (see "BlueRock's PD Purity Play" ). Cell therapy company Celyad S.A....
...team. Kola, who was CSO at UCB S.A. (Euronext:UCB), will lead Forepont's Incubation Fund. BioCentury Staff AACR BlueRock Therapeutics Celyad S.A. Insmed...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...CAR-EGFR/EGFRvIII-T Glioma Ph I/II Killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314) Celyad S.A....
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...Inc. and partners Precision Biosciences Inc. and Servier. (2) Celyad S.A. (NASDAQ:CYAD) is using shRNA; (3) Celyad...
...single editing step using the company's ARCUS homing endonucleases Homing endonucleases Preclinical Other cell engineering Celyad S.A....
...killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314)-based CAR Peptide IND submitted Celyad S.A....
Items per page:
1 - 10 of 93
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...NASDAQ:ALLO) and Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS). A fourth, Celyad S.A....
...those same two genes using TALEN-mediated editing. Celyad’s...
...Inc. Allogene Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. bluebird...
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

...NASDAQ:ALLO) and Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS). A fourth, Celyad S.A....
...those same two genes using TALEN-mediated editing. Celyad’s...
...Tuzman Allogene Therapeutics Inc. Cellectis S.A. Nanjing Bioheng Biotech Co. Ltd. Celyad S.A. CD19 CD22...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...in 1997-2018, most recently serving as a senior medical director. CAR T cell therapy company Celyad S.A....
...CRAC - Calcium release-activated calcium channel Robin Sawka, BioCentury Staff Quell Therapeutics Ltd. American Association for Cancer Research CalciMedica Inc. Celyad S.A. Confo...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...in clinical development and medical affairs at Boehringer Ingelheim GmbH. CAR T cell therapy company Celyad S.A....
...Inc. (NYSE:MRK) from March 2007 to December 2018. BioCentury Staff Applied Therapeutics Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...requiring modification of a patient’s own cells. However, there are nine allogeneic products in development. Celyad S.A....
...ligand 1 TSHR - Thyroid stimulating hormone receptor Winnie Pong, Associate Editor, Data & Analytics Bellicum Pharmaceuticals Inc. Celyad S.A. Programmed...
BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...trial Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A....
...GvHD) among the 12 evaluable patients; one patient experienced grade 1 cytokine release syndrome (CRS). Celyad...
...Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad S.A. Interleukin-2...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad...
...that allows you to do many of those steps in one single transduction.” Christian Homsy, Celyad...
...have made it more feasible to take advantage of its straightforward manufacturing and regulatory path. Celyad S.A....
BioCentury | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

...was acquired by Sanofi (Euronext:SAN; NASDAQ:SNY) (see "BlueRock's PD Purity Play" ). Cell therapy company Celyad S.A....
...team. Kola, who was CSO at UCB S.A. (Euronext:UCB), will lead Forepont's Incubation Fund. BioCentury Staff AACR BlueRock Therapeutics Celyad S.A. Insmed...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...CAR-EGFR/EGFRvIII-T Glioma Ph I/II Killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314) Celyad S.A....
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...Inc. and partners Precision Biosciences Inc. and Servier. (2) Celyad S.A. (NASDAQ:CYAD) is using shRNA; (3) Celyad...
...single editing step using the company's ARCUS homing endonucleases Homing endonucleases Preclinical Other cell engineering Celyad S.A....
...killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314)-based CAR Peptide IND submitted Celyad S.A....
Items per page:
1 - 10 of 93